414 related articles for article (PubMed ID: 12714951)
1. Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
Castellani MR; Cefalo G; Terenziani M; Aliberti G; Maccauro M; Alessi A; Villano C; Bombardieri E
Q J Nucl Med; 2003 Mar; 47(1):22-30. PubMed ID: 12714951
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
Brenot-Rossi I; Bouabdallah R; Di Stefano D; Bardou VJ; Stoppa AM; Camerlo J; Sauvan R; Gastaut JA; Pasquier J
Eur J Nucl Med; 2001 Oct; 28(10):1482-8. PubMed ID: 11685490
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin's disease. Prognostic value of Gallium-67 scintigraphy.
Hervás I; Segura A; López-Tendero P; Bello P; González-Cabezas P; Flores D; Yuste A; Pérez-Velasco R; Girones R; Mateo A
Q J Nucl Med; 2003 Jun; 47(2):101-8. PubMed ID: 12865870
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
5. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
Chajari M; Lacroix J; Peny AM; Chesnay E; Batalla A; Henry-Amar M; Delcambre C; Génot JY; Fruchard C; Bardet S
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):380-7. PubMed ID: 12002715
[TBL] [Abstract][Full Text] [Related]
6. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.
Herman M; Paucek B; Raida L; Myslivecek M; Zapletalová J
Eur J Radiol; 2007 Dec; 64(3):432-8. PubMed ID: 17478069
[TBL] [Abstract][Full Text] [Related]
7. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
Gasparini M; Bombardieri E; Castellani M; Tondini C; Maffioli L; Devizzi L; Gerundini P
J Nucl Med; 1998 Sep; 39(9):1586-90. PubMed ID: 9744348
[TBL] [Abstract][Full Text] [Related]
8. Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study.
Re A; Ferrari S; Frata P; Pizzocaro C; Crippa C; Tucci A; Facchetti F; Grazioli L; Magrini SM; Rossi G
Ann Oncol; 2008 May; 19(5):951-7. PubMed ID: 18209012
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease.
Devizzi L; Maffioli L; Bonfante V; Viviani S; Balzarini L; Gasparini M; Valagussa P; Bombardieri E; Santoro A; Bonadonna G
Ann Oncol; 1997; 8 Suppl 1():53-6. PubMed ID: 9187430
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.
Delcambre C; Reman O; Henry-Amar M; Peny AM; Macro M; Cheze S; Génot JY; Tanguy A; Switsers O; Van HL; Couëtte JE; Leporrier M; Bardet S
Eur J Nucl Med; 2000 Feb; 27(2):176-84. PubMed ID: 10755723
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
[TBL] [Abstract][Full Text] [Related]
12. Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma.
Li S; Beheshti M; Peck-Radosavljevic M; Oezer S; Grumbeck E; Schmid M; Hamilton G; Kapiotis S; Dudczak R; Kletter K
Liver Int; 2006 Oct; 26(8):920-7. PubMed ID: 16953831
[TBL] [Abstract][Full Text] [Related]
13. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Ha CS; Choe JG; Kong JS; Allen PK; Oh YK; Cox JD; Edmund E
Cancer; 2000 Sep; 89(6):1371-9. PubMed ID: 11002233
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease.
King SC; Reiman RJ; Prosnitz LR
J Clin Oncol; 1994 Feb; 12(2):306-11. PubMed ID: 8113837
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
16. Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Yang CC; Sun SS; Lin CC; Kao CH; Lee CC
Anticancer Res; 2001; 21(5):3695-8. PubMed ID: 11848545
[TBL] [Abstract][Full Text] [Related]
17. 111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
Li S; Kurtaran A; Li M; Traub-Weidinger T; Kienast O; Schima W; Angelberger P; Virgolini I; Raderer M; Dudczak R
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1087-95. PubMed ID: 12768334
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate.
Apostolopoulos DJ; Papandrianos NI; Symeonidis A; Spyridonidis T; Alexiou S; Zampakis P; Savvopoulos C; Vassilakos PJ; Matsouka P
Ann Nucl Med; 2010 Nov; 24(9):639-47. PubMed ID: 20799079
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
20. The value of gallium imaging after therapy for Hodgkin's disease.
Bogart JA; Chung CT; Mariados NF; Vermont AI; Lemke SM; Grethlein S; Graziano SL
Cancer; 1998 Feb; 82(4):754-9. PubMed ID: 9477109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
